Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Greggio

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Neurobiology of Disease|April 15, 2022
LRRK2 as a target for modulating immune system responsesIsabella Russo, Luigi Bubacco, Elisa Greggio
Journal of Neuroinflammation|March 25, 2014
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?Isabella Russo, Luigi Bubacco, Elisa Greggio
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 7, 2013
Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapiesMarco Bisaglia, Elisa Greggio, Mariano Beltramini, et al.
Advances in Neurobiology|March 30, 2017
Molecular Insights and Functional Implication of LRRK2 DimerizationLaura Civiero, Isabella Russo, Luigi Bubacco, et al.
Quarterly Reviews of Biophysics|January 22, 2014
Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicityNicoletta Plotegher, Elisa Greggio, Marco Bisaglia, et al.
Molecular Neurodegeneration|January 20, 2011
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?Elisa Greggio, Marco Bisaglia, Laura Civiero, et al.
Journal of Neuroinflammation|May 19, 2012
Parkinson's disease and immune system: is the culprit LRRKing in the periphery?Elisa Greggio, Laura Civiero, Marco Bisaglia, et al.
Biochemical Society Transactions|November 24, 2018
The role of LRRK2 in cytoskeletal dynamicsLaura Civiero, Susanna Cogo, Alice Biosa, et al.
Frontiers in Neuroscience|April 20, 2019
Ceramides in Parkinson's Disease: From Recent Evidence to New HypothesesNicoletta Plotegher, Luigi Bubacco, Elisa Greggio, et al.
Expert Opinion on Therapeutic Targets|June 1, 2022
Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's diseaseJillian H Kluss, Patrick A Lewis, Elisa Greggio
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Neurobiology of Disease|April 15, 2022
LRRK2 as a target for modulating immune system responsesIsabella Russo, Luigi Bubacco, Elisa Greggio
Journal of Neuroinflammation|March 25, 2014
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?Isabella Russo, Luigi Bubacco, Elisa Greggio
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 7, 2013
Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapiesMarco Bisaglia, Elisa Greggio, Mariano Beltramini, et al.
Advances in Neurobiology|March 30, 2017
Molecular Insights and Functional Implication of LRRK2 DimerizationLaura Civiero, Isabella Russo, Luigi Bubacco, et al.
Quarterly Reviews of Biophysics|January 22, 2014
Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicityNicoletta Plotegher, Elisa Greggio, Marco Bisaglia, et al.
Molecular Neurodegeneration|January 20, 2011
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?Elisa Greggio, Marco Bisaglia, Laura Civiero, et al.
Journal of Neuroinflammation|May 19, 2012
Parkinson's disease and immune system: is the culprit LRRKing in the periphery?Elisa Greggio, Laura Civiero, Marco Bisaglia, et al.
Biochemical Society Transactions|November 24, 2018
The role of LRRK2 in cytoskeletal dynamicsLaura Civiero, Susanna Cogo, Alice Biosa, et al.
Frontiers in Neuroscience|April 20, 2019
Ceramides in Parkinson's Disease: From Recent Evidence to New HypothesesNicoletta Plotegher, Luigi Bubacco, Elisa Greggio, et al.
Expert Opinion on Therapeutic Targets|June 1, 2022
Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's diseaseJillian H Kluss, Patrick A Lewis, Elisa Greggio
Pageof 10